Proteinase Activated Receptor 2 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)- Pipeline Review, H2 2019’, provides in depth analysis on Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology under development targeting Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)

– The report reviews Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Hadasit Medical Research Services and Development Ltd

Innovate Biopharmacueticals Inc

Oasis Pharmaceuticals LLC

PeptiDream Inc

Sosei Heptares”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Overview

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Companies Involved in Therapeutics Development

Hadasit Medical Research Services and Development Ltd

Heptares Therapeutics Ltd

IB Pharmaceuticals Inc

PeptiDream Inc

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Drug Profiles

AZ-3451 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-8838 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-88 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larazotide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-2pal18S Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PAR-1 and PAR-2 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PZ-235 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize PAR2 for Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Dormant Products

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) Product Development Milestones

Featured News & Press Releases

May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.

May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference

Dec 28, 2017: Innovate Biopharmaceuticals Dose Response Data for Larazotide Acetate Demonstrating Its Unique Mechanism of Action and Applications in Diseases Caused by Increased Intestinal Permeability

Jun 06, 2017: Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention

Apr 27, 2017: Heptares Collaboration With AstraZeneca Yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation

Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202)

Jan 22, 2015: Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca

Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease

May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease

Mar 17, 2009: Alba Therapeutics Corporation Announces the Next Clinical Trial of its Lead Compound, Larazotide Acetate

Nov 11, 2008: Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

Oct 07, 2008: Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

May 20, 2008: Alba Therapeutics Announces The Presentation Of Results Of A Phase IIa Clinical Trial For Larazotide Acetate For The Treatment Of Celiac Disease

May 16, 2008: Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate for the Treatment of Active Celiac Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019

Pipeline by Innovate Biopharmacueticals Inc, H2 2019

Pipeline by Oasis Pharmaceuticals LLC, H2 2019

Pipeline by PeptiDream Inc, H2 2019

Pipeline by Sosei Heptares, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports